Olsson J E, Müller R, Berneli S
Stroke. 1976 Sep-Oct;7(5):444-51. doi: 10.1161/01.str.7.5.444.
One hundred seventy-eight patients with transient ischemic attacks (TIAs) or small strokes with slight symptoms persisting for more than 24 hours (incomplete recovery = IR) (TIA-IR) from both the carotid and the vertebrobasilar systems were treated with anticoagulants. Ten patients stopped the treatment because of severe side effects. Only one patient had a lethal cerebral infarction when the thrombotest values were above the therapeutic level; no other infarction happened during the treatment period. Moreover, the frequency of TIA decreased during the treatment, compared with descriptions of the natural course of TIA. One hundred four patients were observed for a mean of 21 months after the anticoagulant treatment ended. During the observation period, six patients had cerebral infarctions. This was a sixfold increase compared with the stroke incidence during treatment, and was almost identical with the incidence of strokes seen during the natural course of TIA. All the cerebral infarctions were in patients who had their initial TIA/TIA-IR from the carotid territory (within the same carotid artery which earlier had given symptoms). The investigation shows that long-term anticoagulant treatment is useful, especially in patients with carotid TIA/TIA-IR, and that this treatment should continue as long as the patients can manage it. In patients with vertebrobasilar symptoms of malignant character, it seems feasible to terminate the treatment after about one year. The mechanism of the anticoagulant treatment is obscure, but it does not appear to influence the progress of the atherosclerotic process.
178例患有短暂性脑缺血发作(TIA)或轻微症状持续超过24小时的小卒中(不完全恢复=IR)(TIA-IR)患者,病变累及颈动脉和椎基底动脉系统,接受了抗凝治疗。10例患者因严重副作用而停止治疗。当凝血酶原时间值高于治疗水平时,只有1例患者发生致命性脑梗死;治疗期间未发生其他梗死。此外,与TIA自然病程的描述相比,治疗期间TIA的发作频率有所下降。104例患者在抗凝治疗结束后平均观察了21个月。在观察期内,有6例患者发生脑梗死。这比治疗期间的卒中发生率增加了6倍,几乎与TIA自然病程中观察到的卒中发生率相同。所有脑梗死均发生在最初TIA/TIA-IR来自颈动脉区域的患者中(在先前出现症状的同一颈动脉内)。研究表明,长期抗凝治疗是有效的,尤其是对颈动脉TIA/TIA-IR患者,并且只要患者能够耐受,这种治疗就应持续进行。对于具有恶性特征的椎基底动脉症状患者,在大约一年后终止治疗似乎是可行的。抗凝治疗的机制尚不清楚,但似乎并不影响动脉粥样硬化进程的发展。